13 unknown, 6 recruiting, 5 completed, 5 not yet recruiting. 23 Phase 2, 5 Phase 1, 2 Phase 3, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 23 | Unknown 9, Completed 5, Not yet recruiting 5, Recruiting 4 |
| Phase 1 | 5 | Unknown 3, Not yet recruiting 1, Terminated 1 |
| Phase 3 | 2 | Recruiting 1, Unknown 1 |
| Early Phase 1 | 1 | Unknown 1 |
Follow PD-1: new trials by email Literature Review of PD-1 trials Research Report on PD-1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NCT + PD1 + Ketogenic Diet and/or Vitamin C for LARC Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen - Rectal Adenocarcinoma, High-Risk Cancer | Phase 2 | Not yet recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 100 | 2026-09-01 | 2026-08-14 |
| PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma PD-1+JAK1i, PD-1 - Hodgkin Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Jiao Tong University School of Medicine | 112 | 2026-06-30 | 2026-06-11 |
| SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen - Rectal Adenocarcinoma, High-Risk Cancer | Phase 3 | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 204 | 2026-05-20 | 2026-07-01 |
| Total Neoadjuvant Therapy With PD-1 for Locally Advcancer Rectal Cancer PD-1 - Rectal Cancer Patients | Phase 2 | Not yet recruiting | The First Affiliated Hospital of University of Science and Technology of China | 30 | 2025-10-01 | 2025-10-09 |
| Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer LCRT, SCRT, CAPOX - Colorectal Cancer | Phase 2 | Recruiting | Fudan University | 138 | 2025-08-01 | 2025-09-04 |
| Rimegepant Combined With PD-1 in Liver Metastasis Colorectal Cancer Patients Rimegepant, PD-1 - Colon Cancer | Phase 2 | Not yet recruiting | Fudan University | 20 | 2025-07-01 | 2025-05-31 |
| SCRT+mFOLFOX6+PD-1 Antibody and Targeted Therapy for High-Risk pMMR/MSS Rectal Cancer Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen - Rectal Adenocarcinoma, High-Risk Cancer | Phase 2 | Completed | Sixth Affiliated Hospital, Sun Yat-sen University | 49 | 2025-04-02 | 2026-08-04 |
| PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients PD-1, Nab-paclitaxel, Gemcitabine - Pancreatic Cancer | Phase 2 | Recruiting | Fudan University | 81 | 2024-06-01 | 2024-06-25 |
| A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma BL-B01D1, PD-1 - Urothelial Carcinoma | Phase 2 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 52 | 2024-05-29 | 2026-07-23 |
| Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients Everolimus, PD-1 - Colon Cancer | Phase 2 | Not yet recruiting | Fudan University | 25 | 2024-04-01 | 2024-03-08 |
| A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid Tumors PD-1, MET inhibitor, ALK inhibitor - Patients With Advanced Solid Tumor, Advanced Solid Tumor With Oncogenic Driver Mutations | Phase 2 | Unknown | Suzhou Genhouse Bio Co., Ltd. | 72 | 2024-03-22 | 2024-10-01 |
| HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL) Tislelizumab, Lenvatinib - Hepatocellular Carcinoma With PVTT | Phase 2 | Unknown | Li Xiao Wei | 54 | 2024-03-01 | 2024-02-20 |
| Pembrolizumab for Advanced NSCLC and PS 2-3 Pembrolizumab - Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 45 | 2023-12-05 | 2026-06-15 |
| Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy iNKT Cells, PD-1, Regorafenib - Hepatocellular Carcinoma | Phase 2 | Unknown | Beijing YouAn Hospital | 84 | 2023-10-26 | 2024-01-16 |
| Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer GLS-012+GLS-010, GLS-012+GLS-010+pemetrexed+carboplatin, GLS-012+GLS-010+paclitaxel+carboplatin - Advanced Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Unknown | Guangzhou Gloria Biosciences Co., Ltd. | 152 | 2023-08-10 | 2023-08-07 |
| The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy PD-1, SCRT, Bevacizumab - Rectal Cancer | Phase 2 | Unknown | Fujian Cancer Hospital | 30 | 2023-05-01 | 2022-12-07 |
| Safety and Efficacy of TRPP Therapy in Glioblastoma Multiforme TMZ - Glioblastoma Multiforme | Early Phase 1 | Unknown | The Second Hospital of Hebei Medical University | 10 | 2022-10-01 | 2022-10-21 |
| Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma Sintilimab (PD-1 Antibody) - Nasopharyngeal Carcinoma, Sintilimab | Recruiting | Cancer Hospital of Guangxi Medical University | 43 | 2022-07-30 | 2023-02-01 | |
| HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT HAIC, Lenvatinib 1, PD-1 Inhibitors - Hepatocellular Carcinoma, Portal Vein Thrombosis | Phase 2 | Completed | Peking University | 66 | 2022-01-10 | 2026-01-23 |
| Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma Apatinib mesylate tablet, PD-1 - Nasopharyngeal Carcinoma | Phase 2 | Completed | Wei Jiang | 25 | 2021-01-14 | 2023-01-13 |
Showing 20 of 30. Sign in to see all of them.
Carcinoma, Hepatocellular (4) · Rectal Neoplasms (4) · Colonic Neoplasms (2) · Nasopharyngeal Carcinoma (2) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Glioblastoma (1) · Glioma (1) · Hodgkin Disease (1) · Pancreatic Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Fudan University (4) · Sixth Affiliated Hospital, Sun Yat-sen University (3) · Guangxi Medical University (2) · Peking University (2) · Beijing YouAn Hospital (1) · Cancer Hospital of Guangxi Medical University (1) · Fujian Cancer Hospital (1) · Guangzhou Gloria Biosciences Co., Ltd. (1) · Icahn School of Medicine at Mount Sinai (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Li Xiao Wei (1) · Shanghai Jiao Tong University School of Medicine (1) · Sichuan Baili Pharmaceutical Co., Ltd. (1) · Sinocelltech Ltd. (1) · Sir Run Run Shaw Hospital (1)
China (25) · United States (2)
Alfredo Urdaneta, M.D. (1) · Bailey Fitzgerald, MD (1) · Chunyan Li, Academician (1) · Dawei Li, PhD (1) · Deborah Doroshow, MD, PhD (1) · Dingwei Ye (1) · Guohui Wan, PhD. (1) · Haidan Wang, Doctorate (1) · Jian Zhai, MM (1) · Juan Huang, PhD. (1) · Jun Huang, PhD (1) · Jun Huang, PhD. (1) · Jun Lu, MD. (1) · Ling Li, Master (1) · Ning Li, Doctorate (1)
P30CA016059 (1)